Exploring Variability in Rifampicin Plasma Exposure and Development of Anti-Tuberculosis Drug-Induced Liver Injury Among Patients with Pulmonary Tuberculosis from the Pharmacogenetic Perspective

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2024 Mar 28

PMID 38543282

Authors

Agnija Kivrane

Viktorija Ulanova

Solveiga Grinberga

Eduards Sevostjanovs

Anda Viksna

Iveta Ozere

Ineta Bogdanova

Maksims Zolovs

Renate Ranka

Affiliations

Soon will be listed here.

Abstract

Genetic polymorphisms can exert a considerable impact on drug pharmacokinetics (PK) and the development of adverse drug reactions (ADR). However, the effect of genetic polymorphisms on the anti-tuberculosis (anti-TB) drug, and particularly rifampicin (RIF), exposure or anti-TB drug-induced liver injury (DILI) remains uncertain. Here, we evaluated the relationship between single nucleotide polymorphisms (SNPs) detected in the RIF pharmacogenes (, , , , and ) and RIF PK parameters, as well as anti-TB treatment-associated DILI. In total, the study enrolled 46 patients with drug-susceptible pulmonary TB. The RIF plasma concentration was measured using the LC-MS/MS method in the blood samples collected pre-dose and 2 and 6 h post-dose, whilst the DILI status was established using the results from blood biochemical analysis performed before and 10-12 days after treatment onset. The genotyping was conducted using a targeted NGS approach. After adjustment for confounders, the patients carrying the rs3732357 GA/AA genotype of the gene were found to have significantly lower RIF plasma AUC in comparison to those with GG genotype, while the difference in RIF plasma C was insignificant. None of the analyzed SNPs was related to DILI. Hence, we are the first to report intronic SNP rs3732357 as the genetic component of variability in RIF exposure. Regarding anti-TB treatment-associated DILI, the other preexisting factors promoting this ADR should be considered.

References

Allegra S, Fatiguso G, Calcagno A, Baietto L, Motta I, Favata F . Role of vitamin D pathway gene polymorphisms on rifampicin plasma and intracellular pharmacokinetics. Pharmacogenomics. 2017; 18(9):865-880. DOI: 10.2217/pgs-2017-0176. View

Yimer G, Ueda N, Habtewold A, Amogne W, Suda A, Riedel K . Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients. PLoS One. 2011; 6(12):e27810. PMC: 3232196. DOI: 10.1371/journal.pone.0027810. View

Cramer J, Lohse A, Burchard G, Fischer L, Nashan B, Zimmermann M . Low N-acetyltransferase 2 activity in isoniazid-associated acute hepatitis requiring liver transplantation. Transpl Int. 2009; 23(2):231-3. DOI: 10.1111/j.1432-2277.2009.00921.x. View

Rana M, Coshic P, Goswami R, Tyagi R . Influence of a critical single nucleotide polymorphism on nuclear receptor PXR-promoter function. Cell Biol Int. 2017; 41(5):570-576. DOI: 10.1002/cbin.10744. View

Medellin-Garibay S, Huerta-Garcia A, Rodriguez-Baez A, Magana-Aquino M, Ortiz-Alvarez A, Portales-Perez D . A population approach of rifampicin pharmacogenetics and pharmacokinetics in Mexican patients with tuberculosis. Tuberculosis (Edinb). 2020; 124:101982. DOI: 10.1016/j.tube.2020.101982. View

Barraclough K, Isbel N, Lee K, Bergmann T, Johnson D, McWhinney B . NR1I2 polymorphisms are related to tacrolimus dose-adjusted exposure and BK viremia in adult kidney transplantation. Transplantation. 2012; 94(10):1025-32. DOI: 10.1097/TP.0b013e31826c3985. View

Fahimi F, Tabarsi P, Kobarfard F, Bozorg B, Goodarzi A, Dastan F . Isoniazid, rifampicin and pyrazinamide plasma concentrations 2 and 6 h post dose in patients with pulmonary tuberculosis. Int J Tuberc Lung Dis. 2013; 17(12):1602-6. DOI: 10.5588/ijtld.13.0019. View

Devarbhavi H, Singh R, Patil M, Sheth K, Adarsh C, Balaraju G . Outcome and determinants of mortality in 269 patients with combination anti-tuberculosis drug-induced liver injury. J Gastroenterol Hepatol. 2012; 28(1):161-7. DOI: 10.1111/j.1440-1746.2012.07279.x. View

Walubo A, Chan K, Woo J, Chan H, Wong C . The disposition of antituberculous drugs in plasma of elderly patients. II. Isoniazid, rifampicin and pyrazinamide. Methods Find Exp Clin Pharmacol. 1991; 13(8):551-6. View

10.

McDonagh E, Boukouvala S, Aklillu E, Hein D, Altman R, Klein T . PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2. Pharmacogenet Genomics. 2014; 24(8):409-25. PMC: 4109976. DOI: 10.1097/FPC.0000000000000062. View

11.

Wang N, Guo S, Liu H, Ding Y, Yao R, Liu Z . Relevance of gene polymorphisms of NAT2 and NR1I2 to anti-tuberculosis drug-induced hepatotoxicity. Xenobiotica. 2022; 52(5):520-526. DOI: 10.1080/00498254.2022.2092783. View

12.

Dompreh A, Tang X, Zhou J, Yang H, Topletz A, Adu Ahwireng E . Effect of Genetic Variation of on Isoniazid and and on Rifampin Pharmacokinetics in Ghanaian Children with Tuberculosis. Antimicrob Agents Chemother. 2017; 62(3). PMC: 5826147. DOI: 10.1128/AAC.02099-17. View

13.

Campbell S, de Morais S, Xu J . Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia. Chem Biol Interact. 2004; 150(2):179-87. DOI: 10.1016/j.cbi.2004.08.008. View

14.

Um S, Lee S, Kwon S, Yoon H, Park K, Song J . Low serum concentrations of anti-tuberculosis drugs and determinants of their serum levels. Int J Tuberc Lung Dis. 2007; 11(9):972-8. View

15.

Chen R, Wang J, Tang S, Zhang Y, Lv X, Wu S . Association of polymorphisms in drug transporter genes (SLCO1B1 and SLC10A1) and anti-tuberculosis drug-induced hepatotoxicity in a Chinese cohort. Tuberculosis (Edinb). 2014; 95(1):68-74. DOI: 10.1016/j.tube.2014.11.004. View

16.

He P, Court M, Greenblatt D, von Moltke L . Human pregnane X receptor: genetic polymorphisms, alternative mRNA splice variants, and cytochrome P450 3A metabolic activity. J Clin Pharmacol. 2006; 46(11):1356-69. DOI: 10.1177/0091270006292125. View

17.

Ma X, Idle J, Gonzalez F . The pregnane X receptor: from bench to bedside. Expert Opin Drug Metab Toxicol. 2008; 4(7):895-908. PMC: 2535920. DOI: 10.1517/17425255.4.7.895. View

18.

Afgan E, Baker D, Batut B, van den Beek M, Bouvier D, cech M . The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2018 update. Nucleic Acids Res. 2018; 46(W1):W537-W544. PMC: 6030816. DOI: 10.1093/nar/gky379. View

19.

Chan S, Chua A, Aminkeng F, Chee C, Jin S, Loh M . Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients. PLoS One. 2017; 12(10):e0186200. PMC: 5642896. DOI: 10.1371/journal.pone.0186200. View

20.

Yang H, Wang K . Genomic variant annotation and prioritization with ANNOVAR and wANNOVAR. Nat Protoc. 2015; 10(10):1556-66. PMC: 4718734. DOI: 10.1038/nprot.2015.105. View